share_log

港股异动 | 东阳光药盘中涨超9%创20个月新高 机构大升其目标价

Changes in Hong Kong stocks | Dongguang Pharmaceutical rose more than 9% in the intraday market, hit a 20-month high, and institutions soared their target prices

Gelonghui Finance ·  Mar 14, 2023 11:31
Gelonghui, March 14, 丨 Dongyang Pharmaceutical (1558.HK) bucked the trend in the intraday market and rose more than 9%. The highest price of HK$888 hit a 20-month high. The turnover clearly increased to HK$59.85 million, with a total market capitalization of HK$7.4 billion. Damoyudong Yangguang Pharmaceutical “increased its holdings” rating, raising the target price by 64% to HK$12. The valuation is attractive. Recent data from the US Centers for Disease Control and Prevention (CDC) shows that H1N1, worsening influenza, has reappeared. As the main producer of the influenza antiviral drug “oseltamivir” in the mainland, there is a strong correlation between the company's profit and stock price performance and incidence data. The company's sharp stock-outs and increased production operations suggest that this year will see breakthrough sales growth.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment